---
category: news
title: "FDA breakthrough device designation stimulates increased interest in Sinaptica"
excerpt: "Sinaptica Therapeutics Inc. received a U.S. FDA breakthrough device designation for its electromagnetic therapy for Alzheimer’s disease. Sinaptistim-AD combines neurostimulation, brain wave monitoring and artificial intelligence (AI) to address the cognitive and functional decline in patients with the neurological disorder."
publishedDateTime: 2022-10-19T23:07:00Z
originalUrl: "https://www.bioworld.com/articles/690838-fda-breakthrough-device-designation-stimulates-increased-interest-in-sinaptica"
webUrl: "https://www.bioworld.com/articles/690838-fda-breakthrough-device-designation-stimulates-increased-interest-in-sinaptica"
type: article
quality: 20
heat: 20
published: false

provider:
  name: BioWorld
  domain: bioworld.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-construction-blocks.png?height=635&t=1620679875&width=1200"
    width: 847
    height: 635
    isCached: true

related:
  - title: "Sinaptica’s SinaptiStim – AD Systems Receives Breakthrough Device Status"
    excerpt: "The FDA has granted Sinaptica Therapeutics a Breakthrough Device designation for its SinaptiStim – AD System, an electromagnetic therapy for cognitive and functional decline in Alzheimer’s disease patients."
    publishedDateTime: 2022-10-20T21:36:00Z
    webUrl: "https://www.fdanews.com/articles/209882-sinapticas-sinaptistim-ad-systems-receives-breakthrough-device-status"
    type: article
    provider:
      name: FDAnews
      domain: fdanews.com
    quality: 3
  - title: "Sinaptica Therapeutics Announces FDA Breakthrough Device Designation for its Novel Noninvasive Neurostimulation Treatment for Alzheimer's Disease"
    excerpt: "Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized electromagnetic therapeutics to treat neurodegenerative diseases, today announced the U.S."
    publishedDateTime: 2022-10-19T13:03:00Z
    webUrl: "https://www.tmcnet.com/usubmit/-sinaptica-therapeutics-announces-fda-breakthrough-device-designation-its-/2022/10/19/9695462.htm"
    type: article
    provider:
      name: TMCnet
      domain: tmcnet.com
    quality: 0
    images:
      - url: "https://images.tmcnet.com/webinars/letthegeekspeak/letthegeekspeak_logo.jpg"
        width: 476
        height: 210
        isCached: true

secured: "Zdb+Q1yDIEg/ZSJZ0st7N9rHx1V7WtTxpYf/1Ox4f2q3l9QWatEeF3YVa4rATrlHz6qdYY4bJhXvPOIYboq8PghVBq4eSco7KYOEAlBWwA2Bjcb1JJmBN1q1//p7Re5BcKuvLVJgq2orMj4bl4TfNrMqe0VBqtQRIOlKdllBo/no7/HhS8J5IMAqam5RObskrOCwtqlvqs5QX2xgIZnvGTWLypSKL6u9qB5SN1R59hLmtSFdLRfaLJZoQGtRwnrqtJLKtHNyfywrn/mI/PhKGeWcxudmaIoKiKLk6nzryvGcHsDIGKu4f7nL92dTjehiisKEEJO+iQGp54OjVXmDfHF0J05CJ1TVwOjWT9LGmAY=;GjYjT8LxGYn8rd4orw5kAg=="
---

